PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2494147-7	1989	The degree of injury to cultured endothelial cells by thrombin-stimulated platelets, as measured by release of 51Cr from prelabeled endothelial cells, was reduced significantly with the presence of mannitol, but only moderately when catalase or SOD had been added.	Chromium-51	111-115	coagulation factor II, thrombin	Homo sapiens	54-62
2544300-4	1989	The presence of IL-6 stimulated 51Cr release from labeled, opsonized targets by 67.1% (from 21.6 +/- 1.4% to 36.1 +/- 1.3% at 10 U of IL-6 (P less than 0.01)).	Chromium-51	32-36	interleukin 6	Homo sapiens	16-20
2544300-4	1989	The presence of IL-6 stimulated 51Cr release from labeled, opsonized targets by 67.1% (from 21.6 +/- 1.4% to 36.1 +/- 1.3% at 10 U of IL-6 (P less than 0.01)).	Chromium-51	32-36	interleukin 6	Homo sapiens	134-138
3129432-6	1988	Endothelial cell cultures incubated with PEG-superoxide dismutase and PEG-catalase for 24 h and then extensively washed were protected from the damaging effects of reactive oxygen species derived from exogenous xanthine oxidase as judged by two criteria: decreased release of intracellular 51Cr-labeled proteins and free radical-induced changes in membrane fluidity, measured by electron paramagnetic resonance spectroscopy of endothelial membrane proteins covalently labeled with 4-maleimido-2,2,6,6-tetramethylpiperidinooxyl.	Chromium-51	290-294	catalase	Homo sapiens	74-82
2541081-4	1989	LAK activity was determined by 51Chromium release assay.	Chromium-51	31-41	alpha kinase 1	Homo sapiens	0-3
2848896-4	1988	Results from experiments involving the pre-treatment of LAK cells and target cells (51Cr-labeled target cells or cold-blocking cells) with trypsin, neuraminidase, or sodium periodate suggest that proteins on the surface of LAK cells specifically recognized trypsin-sensitive molecules on the tumor cell surface.	Chromium-51	84-88	neuraminidase 1	Homo sapiens	148-161
3423015-0	1987	Prolonged urinary excretion of 51chromium label from cyclosporine-pretreated human fetal splenocytes following infusion in the NOD mouse.	Chromium-51	31-41	atrophin 1	Homo sapiens	127-130
2833658-6	1988	At a xanthine oxidase concentration of 50 mU/ml, catalase reduced the percentage of 51Cr release from 58.9 +/- 3.1% (SEM) to 7.2 +/- 2.3% (p less than 0.0001), whereas superoxide dismutase was without protection (58.9 +/- 3.1% versus 54.2 +/- 1.8% (p greater than 0.05).	Chromium-51	84-88	catalase	Rattus norvegicus	49-57
6357933-7	1983	Phagocytic activity of adherent cells in PBM against CRBC was enhanced by ReIFN-beta and IFN-beta as determined by microscopical cytologic examination and by the 51Cr-labeled CRBC-uptake method.	Chromium-51	162-166	interferon beta 1	Homo sapiens	76-84
3115019-4	1987	In diabetic patients urinary levels of NAG (356 +/- 25 vs 162 +/- 9.2 nmol/h/mg creatinine, p less than 0.0001) and albumin (21 +/- 2.5 vs 4.3 +/- 0.5 mg/24h, p less than 0.0001) were significantly higher than in the controls, while beta 2-microglobulin levels and 51Cr-EDTA clearance did not differ in the two groups.	Chromium-51	265-269	O-GlcNAcase	Homo sapiens	39-42
3011897-2	1986	The toxin activity of pneumolysin, as determined by lysis of 51Cr-labeled human erythrocytes, was destroyed on exposure to the neutrophil enzyme myeloperoxidase, hydrogen peroxide, and a halide (chloride or iodide).	Chromium-51	61-65	myeloperoxidase	Homo sapiens	145-160
3968424-1	1985	Functionally active natural killer (NK) cells with the ability to lyse 51Cr-labeled YAC-1 lymphoma target cells are no longer detectable by 1 wk of culture in cultured marrow cells harvested from Dexter-type long-term marrow cultures (LMC).	Chromium-51	71-75	ADP-ribosyltransferase 1	Mus musculus	84-89
6487622-4	1984	The enterotoxin-induced release of intracellular 86Rb+ preceded the loss of two larger labels, 51Cr label (Mr approx.	Chromium-51	95-99	cpe	Clostridium perfringens	4-15
3030114-9	1987	When both endothelial catalase and glutathione reductase are inhibited, we detect increased 51Cr release from endothelial cells in response to stimulated neutrophils.	Chromium-51	92-96	glutathione-disulfide reductase	Homo sapiens	35-56
3104392-7	1987	Finally, we examined the response of these cells to interleukin-2 stimulation by generating cells with direct cytotoxicity to 51Cr-labeled Daudi-cell targets.	Chromium-51	126-130	interleukin 2	Homo sapiens	52-65
3753417-2	1986	After reinfusion of 51Cr-labeled platelets of PRP stored in first generation containers and evaluation of in vivo recovery and half life optimum, range of storage temperature was found to be 20-24 degrees C. Storage of PC in first generation containers showed a significant fall of pH which was in a clear relationship to platelet concentration, lactate production, and glucose consumption.	Chromium-51	20-24	prion protein	Homo sapiens	46-49
6488587-5	1984	Cell suspensions were incubated with 51Cr-labeled YAC-1 lymphoma target cells in a 4-hr 51Cr-release assay.	Chromium-51	37-41	ADP-ribosyltransferase 1	Mus musculus	50-55
6831844-5	1983	The retention of 51Cr indicated the efficiency of faecal excretion of unabsorbed B12 tracer and could be used to quantify vitamin B12 absorption before complete excretion of unabsorbed B12 tracer.	Chromium-51	17-21	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	130-133
6222791-2	1983	Functions of the receptors were studied by measuring the adherence and uptake of 51Cr-labeled sheep red blood cells (SRBC) mediated by isolated rat anti-SRBC IgM or IgG2a antibodies and human C3, respectively.	Chromium-51	81-85	gamma-2a immunoglobulin heavy chain	Rattus norvegicus	165-170
6629526-4	1983	Further studies on the reactivity of fibrinogen adsorbed on polyacrylonitrile surface indicated that the absorbed fibrinogen: (a) was not desorbed readily from the surface, (b) was not appreciably displaced by other plasma proteins such as albumin, IgG, and fibrinogen, (c) was not readily accessible for reaction with 125I-antifibrinogen-IgG, and (d) did not promote the adhesion of 51Cr-labeled platelets.	Chromium-51	384-388	fibrinogen beta chain	Homo sapiens	114-124
6629526-4	1983	Further studies on the reactivity of fibrinogen adsorbed on polyacrylonitrile surface indicated that the absorbed fibrinogen: (a) was not desorbed readily from the surface, (b) was not appreciably displaced by other plasma proteins such as albumin, IgG, and fibrinogen, (c) was not readily accessible for reaction with 125I-antifibrinogen-IgG, and (d) did not promote the adhesion of 51Cr-labeled platelets.	Chromium-51	384-388	fibrinogen beta chain	Homo sapiens	114-124
6219064-7	1983	When tested against BW cells, neutrophils have been found to induce high levels of 51Cr release in the presence of IgG1, IgG2a, IgG2b and IgE, but not when IgG3, IgM, IgA or IgD were used.	Chromium-51	83-87	LOC105243590	Mus musculus	115-119
6219064-7	1983	When tested against BW cells, neutrophils have been found to induce high levels of 51Cr release in the presence of IgG1, IgG2a, IgG2b and IgE, but not when IgG3, IgM, IgA or IgD were used.	Chromium-51	83-87	immunoglobulin heavy variable V1-9	Mus musculus	121-126
6219064-7	1983	When tested against BW cells, neutrophils have been found to induce high levels of 51Cr release in the presence of IgG1, IgG2a, IgG2b and IgE, but not when IgG3, IgM, IgA or IgD were used.	Chromium-51	83-87	immunoglobulin heavy constant gamma 2B	Mus musculus	128-133
6831844-3	1983	A non-absorbable tracer, 51Cr-chromic chloride, was administered firstly with 58Co-labelled vitamin B12 and then three hours later with 57Co-labelled vitamin B12 and then three hours later with 57Co-labelled vitamin B12 plus 50 mg hog intrinsic factor which normalises B12 malabsorption in patients with pernicious anaemia.	Chromium-51	25-29	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	100-103
6831844-3	1983	A non-absorbable tracer, 51Cr-chromic chloride, was administered firstly with 58Co-labelled vitamin B12 and then three hours later with 57Co-labelled vitamin B12 and then three hours later with 57Co-labelled vitamin B12 plus 50 mg hog intrinsic factor which normalises B12 malabsorption in patients with pernicious anaemia.	Chromium-51	25-29	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	158-161
6831844-3	1983	A non-absorbable tracer, 51Cr-chromic chloride, was administered firstly with 58Co-labelled vitamin B12 and then three hours later with 57Co-labelled vitamin B12 and then three hours later with 57Co-labelled vitamin B12 plus 50 mg hog intrinsic factor which normalises B12 malabsorption in patients with pernicious anaemia.	Chromium-51	25-29	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	158-161
6831844-3	1983	A non-absorbable tracer, 51Cr-chromic chloride, was administered firstly with 58Co-labelled vitamin B12 and then three hours later with 57Co-labelled vitamin B12 and then three hours later with 57Co-labelled vitamin B12 plus 50 mg hog intrinsic factor which normalises B12 malabsorption in patients with pernicious anaemia.	Chromium-51	25-29	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	158-161
6831844-5	1983	The retention of 51Cr indicated the efficiency of faecal excretion of unabsorbed B12 tracer and could be used to quantify vitamin B12 absorption before complete excretion of unabsorbed B12 tracer.	Chromium-51	17-21	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	81-84
6831844-5	1983	The retention of 51Cr indicated the efficiency of faecal excretion of unabsorbed B12 tracer and could be used to quantify vitamin B12 absorption before complete excretion of unabsorbed B12 tracer.	Chromium-51	17-21	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	130-133
749930-5	1978	Plasma PF4 levels are markedly increased during cardiopulmonary bypass surgery with shortened 51Cr-labelled platelet survival times and during arterial thrombosis.	Chromium-51	94-98	platelet factor 4	Homo sapiens	7-10
7179206-4	1982	EC exposed to thrombin pretreated with N-bromosuccinimide (modifying the macromolecular site) or phenylmethylsulfonyl fluoride (blocking the serine site) retained normal morphology and did not leak excess amounts of 51Cr.	Chromium-51	216-220	coagulation factor II, thrombin	Homo sapiens	14-22
7127901-7	1982	The simultaneous addition of superoxide dismutase and catalase in the cell culture decreased the 51Cr release to control levels.	Chromium-51	97-101	catalase	Homo sapiens	54-62
401462-4	1977	Lysis of platelets did not occur, since less than 1% of the platelet-bound 51Cr from platelets labeled with this radioisotope appeared in the ambient fluid upon thrombin treatment.	Chromium-51	75-79	coagulation factor II, thrombin	Homo sapiens	161-169
908456-0	1977	The spontaneous release of 51Cr from labeled EL-4 ascitic lymphoma cells as dependent upon the composition of the cell population.	Chromium-51	27-31	epilepsy 4	Mus musculus	45-49
908456-1	1977	Investigations on the spontaneous release of 51Cr from the EL-4 ascitic lymphoma showed that daily rhythmic changes can be correlated with the dominance of certain cell types in the population.	Chromium-51	45-49	epilepsy 4	Mus musculus	59-63
21992070-6	2011	RESULTS: Plasma clearances of 51Cr-EDTA for all patients ranged between 2.1 and 30.8 mL/min/1.73 m2, whereas urinary 51Cr-EDTA clearances ranged from 0.7-20.0 mL/min/1.73 m2.	Chromium-51	30-34	CD59 molecule (CD59 blood group)	Homo sapiens	88-93
33486611-5	2021	The ability of CD8 + T cells to kill target ATC cells was detected by Chromium-51 (51Cr) release assay.	Chromium-51	70-81	CD8a molecule	Homo sapiens	15-18
33486611-5	2021	The ability of CD8 + T cells to kill target ATC cells was detected by Chromium-51 (51Cr) release assay.	Chromium-51	83-87	CD8a molecule	Homo sapiens	15-18
950096-6	1976	Lymphocytes from approximately 50% of the patients with PBC exhibited cytotoxicity for hepatic cells but 25% showed less 51Cr release than controls and the remaining patients had results in the normal range.	Chromium-51	121-125	dihydrolipoamide S-acetyltransferase	Homo sapiens	56-59
12182558-5	2002	Changes in fibrinogen reactivity were determined by measuring the adhesion of 51Cr-labeled platelets and the ability of blood plasma to displace previously adsorbed fibrinogen.	Chromium-51	78-82	fibrinogen beta chain	Homo sapiens	11-21
10385508-8	1999	TNF injection markedly reduced the survival and increased the pulmonary localization of 51Cr-labeled platelets from +/+ but not from uPAR-/- donors, indicating that it is the platelet uPAR that is critical for their response to TNF.	Chromium-51	88-92	tumor necrosis factor	Mus musculus	0-3
11697114-6	2001	Moreover, exogenous recombinant wild type TRX decreased 51Cr release from primary cultured rat gastric mucosal cells incubated with ethanol or hydrogen peroxide in a dose-dependent manner, whereas recombinant mutant TRX (C32S/C35S), in which the two cysteines were replaced with serines in its active site, did not.	Chromium-51	56-60	thioredoxin 1	Rattus norvegicus	42-45
11079521-3	2000	In vivo cytotoxicity was measured as clearance of injected 51Cr-labeled YAC-1 lymphoma cells from the lungs.	Chromium-51	59-63	ADP-ribosyltransferase 1	Mus musculus	72-77
10804823-7	2000	The correlation coefficient between cytotoxicity values by this ALP synthesis assay and those by 51Cr release assay was 0.93.	Chromium-51	97-101	ATHS	Homo sapiens	64-67
10452279-3	1999	Recently published studies have shown that cystatin C correlates more strongly than creatinine with GFR measured using the 51Cr-EDTA clearance.	Chromium-51	123-127	cystatin C	Homo sapiens	43-53
10385508-8	1999	TNF injection markedly reduced the survival and increased the pulmonary localization of 51Cr-labeled platelets from +/+ but not from uPAR-/- donors, indicating that it is the platelet uPAR that is critical for their response to TNF.	Chromium-51	88-92	plasminogen activator, urokinase receptor	Mus musculus	184-188
9972924-3	1999	Mice of B6C3F1 strain were treated with different doses of NNK by IP and assayed for natural killer cell activity by the lysis of 51Cr-labeled YAC-1 lymphoma cells.	Chromium-51	130-134	ADP-ribosyltransferase 1	Mus musculus	143-148
10397927-5	1999	Changes in fibrinogen reactivity were determined by measuring the adhesion of 51Cr-labeled platelets, the binding of a monoclonal antibody (mAb) directed against an important functional region of the fibrinogen molecule (the gamma-chain dodecapeptide sequence 400-411), and the ability of blood plasma to displace previously adsorbed fibrinogen.	Chromium-51	78-82	fibrinogen beta chain	Homo sapiens	11-21
9365155-5	1997	Unidirectional flux of [51Cr]EDTA was 6- to 22-fold greater in the ileum of sialoadenectomized mice, which was prevented by EGF administration.	Chromium-51	24-28	epidermal growth factor	Mus musculus	124-127
9834271-5	1998	IELs lysed more 51Cr-labeled HT-29 cells when cultured for 72 hours with IL-15 (48% +/- 3% at 25:1 effector-to-target ratio) than with IL-2 (27% +/- 3%) or IL-7 (12% +/- 2%) (P < 0.0001).	Chromium-51	16-20	interleukin 15	Homo sapiens	73-78
9686583-5	1998	Pretreatment of 51Cr-labeled lymphocytes from BALB/c mice with H32 significantly inhibited their homing to lymph nodes in vivo.	Chromium-51	16-20	histocompatibility 32	Mus musculus	63-66
9062508-11	1997	In assays for antibody-dependent cytotoxicity using PBMC, 51Cr release was higher for thyroid cells preincubated with IgG1-SP (13.4%) than with IgG4-SP (2.5%) or with culture medium alone (-0.7%).	Chromium-51	58-62	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	118-122
8825801-4	1996	In controls, the stomach contained 26.1 +/- 1.6% (mean +/- SEM); in EGF-treated rats the stomach contained 75.9 +/- 10.2% and 75.7 +/- 2.5% of the total 51Cr-EDTA counts given.	Chromium-51	153-157	epidermal growth factor like 1	Rattus norvegicus	68-71
8970973-6	1996	We report that a phosphorothioate-modified antisense oligonucleotide specific for cPLA2, but not the control oligonucleotide, inhibited the TNF-induced release of both [3H]arachidonic acid and 51Cr from infected cells.	Chromium-51	193-197	phospholipase A2 group IVA	Homo sapiens	82-87
8970973-6	1996	We report that a phosphorothioate-modified antisense oligonucleotide specific for cPLA2, but not the control oligonucleotide, inhibited the TNF-induced release of both [3H]arachidonic acid and 51Cr from infected cells.	Chromium-51	193-197	tumor necrosis factor	Homo sapiens	140-143
8970973-7	1996	Arachidonyltrifluoromethyl ketone (AA COCF3), an inhibitor of cPLA2, also inhibited the release of 51Cr, and we found that the release of [3H]arachidonic acid was highly selective and was preferred over the release of [3H]palmitic acid.	Chromium-51	99-103	phospholipase A2 group IVA	Homo sapiens	62-67
8858989-7	1996	administration of 51Cr-labeled proteins into mice, native SOD was excreted rapidly into urine and no significant accumulation was observed in organs other than the kidneys.	Chromium-51	18-22	superoxide dismutase 1	Homo sapiens	58-61
8879340-4	1996	In a recent prospective, randomized, double blind trial in 257 patients with essential hypertension, the loss of GFR, determined with 51Cr-EDTA clearance, was significantly less with an ACE inhibitor (cilazapril) than with a beta-adrenoceptor blocker (atenolol) during the first year of treatment.	Chromium-51	134-138	angiotensin I converting enzyme	Homo sapiens	186-189
8613675-8	1996	The assay can be performed in a few hours and has the advantage over the current MTT and 51Cr-released assays that kinetic studies of TNF-alpha toxicity are possible since it permits multiple, sequenced measurements of cell viability during the incubation of the sample.	Chromium-51	89-93	tumor necrosis factor	Mus musculus	134-143
7768980-7	1995	These results suggest that the mechanism which mediates the efflux of 51Cr-labeled proteins from ATP-lysed macrophages is distinct from calcium mobilization and membrane depolarization, and may involve the generation of secondary pores/channels in the plasma membrane via a calmodulin-linked pathway.	Chromium-51	70-74	calmodulin 1	Homo sapiens	274-284
8865154-9	1996	Moreover, the cytotoxic activity of the M phi s (H-2b) against 51Cr-labeled Meth A (H-2d) cells was inhibited by the addition of unlabeled H-2d, but not H-2b, H-2k or H-2h, lymphoblasts as well as Meth A cells, implying the specific interaction of the M phi s with H-2d cells.	Chromium-51	63-67	histocompatibility 2, K1, K region	Mus musculus	159-163
8773199-2	1995	In these fish, whose isogenicity was previously confirmed by multilocus DNA fingerprint analysis, NCC activity was studied by the release of 51Cr from YAC-1 targets.	Chromium-51	141-145	ADP-ribosyltransferase 1	Mus musculus	151-156
7759886-5	1995	injection, large numbers of 51Cr-labeled blood monocytes migrated within 2 h to dermal inflammatory sites induced by C5a, IL-1 alpha, IFN-gamma, TNF-alpha, LPS, and poly inosinic:cytidylic acid.	Chromium-51	28-32	complement C5	Rattus norvegicus	117-120
7759886-5	1995	injection, large numbers of 51Cr-labeled blood monocytes migrated within 2 h to dermal inflammatory sites induced by C5a, IL-1 alpha, IFN-gamma, TNF-alpha, LPS, and poly inosinic:cytidylic acid.	Chromium-51	28-32	interleukin 1 alpha	Rattus norvegicus	122-132
7759886-5	1995	injection, large numbers of 51Cr-labeled blood monocytes migrated within 2 h to dermal inflammatory sites induced by C5a, IL-1 alpha, IFN-gamma, TNF-alpha, LPS, and poly inosinic:cytidylic acid.	Chromium-51	28-32	interferon gamma	Rattus norvegicus	134-143
7759886-5	1995	injection, large numbers of 51Cr-labeled blood monocytes migrated within 2 h to dermal inflammatory sites induced by C5a, IL-1 alpha, IFN-gamma, TNF-alpha, LPS, and poly inosinic:cytidylic acid.	Chromium-51	28-32	tumor necrosis factor	Rattus norvegicus	145-154
7707422-8	1995	The in vivo effect of intravenously injected rPF4 on the retention of 51Cr-labeled B16F10 cells was examined by determining the remaining lung-associated radioactivity after 30 minutes or 1, 2, or 4 hours.	Chromium-51	70-74	platelet factor 4	Rattus norvegicus	45-49
7533816-9	1995	IL-2 retarded the time dependent decrease of ATP and 51Cr release levels after irradiation.	Chromium-51	53-57	interleukin 2	Homo sapiens	0-4
7771646-11	1995	Ethanol exposure had no significant effect on the kinetics of acquisition of NK lytic function, as assessed by determining the killing of chromium-51 labeled YAC-1 tumor target cells.	Chromium-51	138-149	ADP-ribosyltransferase 1	Mus musculus	158-163
7954462-12	1994	Up to 80% specific 51Cr release was achieved using either freshly isolated human peripheral blood mononuclear cells or 2-day-old interleukin 2-stimulated human peripheral blood mononuclear cells as effectors.	Chromium-51	19-23	interleukin 2	Homo sapiens	129-142
7525102-7	1994	Furthermore, when TNF-alpha stimulated endothelial cells labeled with 51Cr were incubated with antibody II-13 in the presence of complement, significant lysis occurred.	Chromium-51	70-74	tumor necrosis factor	Rattus norvegicus	18-27
8034601-2	1994	Human neutrophils, when exposed to tumor necrosis factor-alpha and the complement compound C5a, induced endothelial damage assessed by the release of 51Cr into the medium.	Chromium-51	150-154	complement C5a receptor 1	Homo sapiens	91-94
8034601-2	1994	Human neutrophils, when exposed to tumor necrosis factor-alpha and the complement compound C5a, induced endothelial damage assessed by the release of 51Cr into the medium.	Chromium-51	150-154	tumor necrosis factor	Homo sapiens	35-62
1326736-9	1992	This increase in 51Cr release was inhibited by catalase, a scavenger of hydrogen peroxide, or dimethyl sulfoxide, a scavenger of hydroxyl radicals, but not by superoxide dismutase, a scavenger of superoxide, nor deferoxamine, an inhibitor of hydroxyl radical generation.	Chromium-51	17-21	catalase	Rattus norvegicus	47-55
7976660-1	1994	The vasoactive peptide endothelin-1 (ET-1) dose-dependently increased release of 51Cr from human cerebromicrovascular endothelial cells (HBEC), without affecting cell viability as assessed by lactate dehydrogenase release.	Chromium-51	81-85	endothelin 1	Homo sapiens	23-35
7976660-1	1994	The vasoactive peptide endothelin-1 (ET-1) dose-dependently increased release of 51Cr from human cerebromicrovascular endothelial cells (HBEC), without affecting cell viability as assessed by lactate dehydrogenase release.	Chromium-51	81-85	endothelin 1	Homo sapiens	37-41
8261833-7	1993	The addition of superoxide dismutase caused a further increase in 51Cr release, oxidized glutathione, and shunt activity (P < 0.01), which was prevented by the addition of catalase or mannitol.	Chromium-51	66-70	catalase	Homo sapiens	175-183
8447814-2	1993	ET-1 induced dose-dependent release of 51CR (EC50 = 7 +/- 2 nM), transient increase of IP3 (EC50 = 0.67 +/- 0.09 nM), and sustained release of AA (EC50= 59 +/- 7 nM) from HBEC.	Chromium-51	39-43	endothelin 1	Homo sapiens	0-4
8447814-5	1993	Protein kinase C (PKC) inhibitor H7 (200 nM), calcium channel blocker verapamil (10 microM), or IP3 receptor antagonist ryonidine (5 microM) reduced ET-1 (100 nM)-induced release of 51Cr.	Chromium-51	182-186	endothelin 1	Homo sapiens	149-153
1434539-8	1992	Slight but significant transendothelial migration of 51Cr-labeled PMNL was induced by alpha-thrombin (7.4 +/- 0.6% of cells added, unstimulated = 1.9 +/- 0.4%), although this response was less than that induced by f-norLeu-Leu-Phe (17%), IL-1 alpha (29%) or TNF-alpha (21%).	Chromium-51	53-57	coagulation factor II, thrombin	Homo sapiens	92-100
1434539-8	1992	Slight but significant transendothelial migration of 51Cr-labeled PMNL was induced by alpha-thrombin (7.4 +/- 0.6% of cells added, unstimulated = 1.9 +/- 0.4%), although this response was less than that induced by f-norLeu-Leu-Phe (17%), IL-1 alpha (29%) or TNF-alpha (21%).	Chromium-51	53-57	interleukin 1 alpha	Homo sapiens	238-248
1434539-8	1992	Slight but significant transendothelial migration of 51Cr-labeled PMNL was induced by alpha-thrombin (7.4 +/- 0.6% of cells added, unstimulated = 1.9 +/- 0.4%), although this response was less than that induced by f-norLeu-Leu-Phe (17%), IL-1 alpha (29%) or TNF-alpha (21%).	Chromium-51	53-57	tumor necrosis factor	Homo sapiens	258-267
8095165-4	1993	When interleukin-2 (IL-2)-stimulated PBMC were assayed for their cytotoxicity against 51Cr-labeled allogeneic and autologous CD13+ AML cells, their activity was markedly enhanced by the addition of the BsAb.	Chromium-51	86-90	interleukin 2	Homo sapiens	5-18
8095165-4	1993	When interleukin-2 (IL-2)-stimulated PBMC were assayed for their cytotoxicity against 51Cr-labeled allogeneic and autologous CD13+ AML cells, their activity was markedly enhanced by the addition of the BsAb.	Chromium-51	86-90	interleukin 2	Homo sapiens	20-24
8095165-4	1993	When interleukin-2 (IL-2)-stimulated PBMC were assayed for their cytotoxicity against 51Cr-labeled allogeneic and autologous CD13+ AML cells, their activity was markedly enhanced by the addition of the BsAb.	Chromium-51	86-90	alanyl aminopeptidase, membrane	Homo sapiens	125-129
8393545-7	1993	GFR measured by the urinary clearance of [51Cr]-EDTA was identical in the two groups at the start of the study: compliant patients 15.7 +/- 5.3 ml/mn, non-compliant patients 15.4 +/- 5.9 ml/mn.	Chromium-51	41-48	Rap guanine nucleotide exchange factor 5	Homo sapiens	0-3
1335700-5	1992	At 8 ng PMA/ml, ACE activity was totally abolished, without any evidence of cytotoxicity, as inferred from release of 51Cr from prelabeled EC.	Chromium-51	118-122	angiotensin-converting enzyme	Oryctolagus cuniculus	16-19
1295362-5	1992	This human MBP caused modest, but statistically significant, damage to respiratory epithelium (16.4% increase in efflux of 51Cr from guinea-pig tracheal rings) after 3 h of incubation with 10(-4) M concentration, but not with lower concentrations.	Chromium-51	123-127	myelin basic protein	Homo sapiens	11-14
1762305-0	1991	Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance.	Chromium-51	55-59	Rap guanine nucleotide exchange factor 5	Homo sapiens	17-20
1319618-5	1992	Addition of leukocytes stimulated with endotoxin plus FMLP to cultured endothelial cells induced release of TM antigen to the medium accompanying cell injury as measured by 51Cr release, which was prevented by treatment with heparin.	Chromium-51	173-177	thrombomodulin	Oryctolagus cuniculus	108-110
1536778-5	1992	When the interaction with LAK cells was followed by hyperthermia at 43 degrees C, the total release of 51Cr from the cell lines was 75-85%.	Chromium-51	103-107	alpha-kinase 1	Mus musculus	26-29
1762305-3	1991	The change in GFR was followed in 153 patients with repeated determinations of 51Cr-EDTA clearance.	Chromium-51	79-83	Rap guanine nucleotide exchange factor 5	Homo sapiens	14-17
1918978-4	1991	In addition, IFN-gamma-treated macrophages released approximately 80% of 51Cr label within 15 min after the addition of ATPo, whereas GM-CSF-treated cells did not release significant levels of radiolabel until 4 to 6 h after initial stimulation with ATPo.	Chromium-51	73-77	interferon gamma	Homo sapiens	13-22
1918978-6	1991	Thus, IFN-gamma treatment of macrophages elicited increased sensitivity to ATPo-mediated lysis, a phenomenon characterized by rapid release of 51Cr from labeled cells and which is possibly due to induction or activation of surface ATP-binding receptors different from those present on GM-CSF-treated or untreated macrophages.	Chromium-51	143-147	interferon gamma	Homo sapiens	6-15
1918978-6	1991	Thus, IFN-gamma treatment of macrophages elicited increased sensitivity to ATPo-mediated lysis, a phenomenon characterized by rapid release of 51Cr from labeled cells and which is possibly due to induction or activation of surface ATP-binding receptors different from those present on GM-CSF-treated or untreated macrophages.	Chromium-51	143-147	ATP synthase peripheral stalk subunit OSCP	Homo sapiens	75-79
2176255-6	1990	When the cells were exposed to 50 mU/ml xanthine oxidase with 5.0 mM hypoxanthine for five hours, total 51chromium release was significantly (P less than 0.001) greater in LLC-PK1, NHK-C and OK cells compared to MDCK cells, while total 51chromium release was significantly (P less than 0.001) greater in endothelial cells compared to all tubular cells.	Chromium-51	104-114	xanthine dehydrogenase	Sus scrofa	40-56
1647676-5	1991	hSOD, catalase, and deferoxamine reduced the 51Cr-EDTA clearance at each PAF dose and eliminated the dependence of 51Cr-EDTA clearance on transmucosal fluid flux.	Chromium-51	45-49	catalase	Homo sapiens	6-14
1647676-5	1991	hSOD, catalase, and deferoxamine reduced the 51Cr-EDTA clearance at each PAF dose and eliminated the dependence of 51Cr-EDTA clearance on transmucosal fluid flux.	Chromium-51	45-49	PCNA clamp associated factor	Homo sapiens	73-76
1647676-5	1991	hSOD, catalase, and deferoxamine reduced the 51Cr-EDTA clearance at each PAF dose and eliminated the dependence of 51Cr-EDTA clearance on transmucosal fluid flux.	Chromium-51	115-119	catalase	Homo sapiens	6-14
1670626-5	1991	NPY (0.01-10 microM) increased the adhesion of 51Cr-labeled human neutrophils or the human monocytic U937 cell line to human umbilical vein endothelial cells in a dose- and time-dependent manner.	Chromium-51	47-51	neuropeptide Y	Homo sapiens	0-3
2176255-6	1990	When the cells were exposed to 50 mU/ml xanthine oxidase with 5.0 mM hypoxanthine for five hours, total 51chromium release was significantly (P less than 0.001) greater in LLC-PK1, NHK-C and OK cells compared to MDCK cells, while total 51chromium release was significantly (P less than 0.001) greater in endothelial cells compared to all tubular cells.	Chromium-51	236-246	xanthine dehydrogenase	Sus scrofa	40-56
2150407-1	1990	YAC-1 tumor cells double-labeled with Na2[51Cr]O4 [51Cr] and [125I]iododeoxyuridine [125IUdR] were injected intravenously into Balb/c mice in order to investigate their migration and fate 0-4 h after the injection.	Chromium-51	51-55	ADP-ribosyltransferase 1	Mus musculus	0-5
2372057-11	1990	However, in the presence of neutrophils, both SOD and allopurinol attenuated the increases in 51Cr release.	Chromium-51	94-98	superoxide dismutase 1	Homo sapiens	46-49